RECHERCHE
boerse.de
Europas erstes Finanzportal
Aktien-Ausblick
kostenlos, schon >150.000 Leser
boerse.de-Aktienbrief
kostenlos + unverbindlich
Börsendienste
kostenlos + unverbindlich kennenlernen
Leitfaden für Ihr Vermögen
einzigartiges Börsenwissen kostenlos
INVESTMENT
boerse.de-Gold (TMG0LD)
Responsible Gold!
boerse.de-Fonds - ohne Agio!
boerse.de-Aktienfonds
boerse.de-Weltfonds
boerse.de-Technologiefonds
boerse.de-DividendenfondsNEU
boerse.de-Indizes
BCDI -
Das Original!
BCDI
USA
BCDI Deutschland
myChampionsPREMIUM
ab 500.000 Euro
myChampions100
Aktion: Ab 50.000 Euro
ÜBER UNS
SAN DIEGO & GOLETA, Calif. –
Shareholder rights law firm Robbins
Arroyo LLP announces that shareholders of Inogen (NASDAQ: INGN)
filed a class action complaint against the company for alleged
violations of the Securities and Exchange Act of 1934 between November
8, 2017 and February 26, 2019. Inogen is a medical technology company
that primarily develops, manufactures, and markets portable oxygen
concentrators used to deliver supplemental long-term oxygen therapy to
patients.
View this information on the law firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/inogen-mar-19/
Inogen Accused of Misstating its Strong Sales and Financial Success
According to the complaint, on November 7, 2017, Inogen touted its strong sales and financial success, predicting "strong results in 2018…" and increased its guidance range for full year 2017 revenue. Inogen subsequently increased its FY18 guidance range, emphasizing that the company's strong direct-to-customer sales were the result of the strong sales acumen of its salesforce. These quarterly statements were often followed by significant increases in stock price that resulted in a class period high of more than $282 per share on September 14, 2018. In February 2019, a series of news articles were released criticizing the company's narrative and denouncing its sales tactics, negatively affecting the company's stock. Then, on February 26, 2019, Inogen announced poor 4Q18 and FY18 financial results, which caused Inogen's stock to fall nearly $34 per share, or more than 24% to close at $106.28 per share on February 27, 2019. The stock now trades at just $95.71.
Inogen Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leo Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190320005833/en/
Quelle: Business Wireboerse.de-Börsenzitat:
Unterbewertete Aktien suchen Meiden Sie Tipps und verlassen Sie sich nicht auf Gurus. Beherzigen Sie auch den alten Börsenspruch: "Hin und Her macht die Taschen leer!". Genauer gesagt, es macht Ihre Taschen leer und die der Bank oder des Brokers voll! Die größten Gewinne machen Sie mit Aktien, deren Börsenkurs unter dem wahren Wert des Unternehmens liegt.
Ich bin damit einverstanden, dass die TM Börsenverlag AG und die Schwestergesellschaft boerse.de Vermögensverwaltung GmbH
mir regelmäßig Informationen zu aktuellen Produkten und Dienstleistungen aus dem Finanzbereich,
sowie den kostenlosen Newsletter boerse.de-Aktien-Ausblick zuschickt. Meine Einwilligung kann ich
jederzeit gegenüber der TM Börsenverlag AG widerrufen.
Unsere Datenschutzerklärung finden Sie hier.